AIOMEGA

AiOmega is a biotechnology company that leverages artificial intelligence to transform the discovery of therapeutics for age-related diseases. The company's proprietary Omega platform integrates deep learning and generative biology to identify novel targets and design high-affinity small molecules. AiOmega focuses on high-impact therapeutic areas, including oncology, neurodegeneration, and metabolic disorders, with a specific emphasis on extending human healthspan. By automating the early stages of drug development, the company seeks to deliver precision medicines more efficiently than traditional methods. The platform's ability to predict molecular properties and optimize lead compounds aims to reduce the high attrition rates typically seen in drug development.